CymaBay Therapeutics Inc. (CBAY): Price and Financial Metrics


CymaBay Therapeutics Inc. (CBAY): $2.03

0.06 (+3.05%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CBAY to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CBAY Stock Price Chart Interactive Chart >

Price chart for CBAY

CBAY Price/Volume Stats

Current price $2.03 52-week high $5.06
Prev. close $1.97 52-week low $1.67
Day low $1.93 Volume 317,400
Day high $2.03 Avg. volume 495,480
50-day MA $2.59 Dividend yield N/A
200-day MA $3.32 Market Cap 171.90M

CymaBay Therapeutics Inc. (CBAY) Company Bio


Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. The company was formerly known as Metabolex, Inc. The company was founded in 1988 and is based in Newark, California.


CBAY Latest News Stream


Event/Time News Detail
Loading, please wait...

CBAY Latest Social Stream


Loading social stream, please wait...

View Full CBAY Social Stream

Latest CBAY News From Around the Web

Below are the latest news stories about CymaBay Therapeutics Inc that investors may wish to consider to help them evaluate CBAY as an investment opportunity.

CymaBay Therapeutics to Present at Upcoming Investor Conferences

NEWARK, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in two virtual investor conferences including the 11th Annual SVB Leerink Global Healthcare Conference taking place February 14-18, 2022 and Oppenheimer’s 32nd Annual Healthcare Conference taking place March 15-16, 2022. 11t

Yahoo | February 10, 2022

Adult Liver Diseases: The R&D Engine Drives Albireo's Long-Term Prospects.

Although Albireo (ALBO) has an attractive and robust pipeline, I have focused mainly on Odevixibat in my articles so far. In my opinion, this is right, as the approved and revenue generating product Bylvay (Odevixibat in PFIC) is currently the biggest value driver for Albireo and actually justifies more than...

Biotech Fan on Seeking Alpha | February 1, 2022

LCM Capital Management Inc Buys Southern Co, Advanced Micro Devices Inc, Diageo PLC, Sells ...

Investment company LCM Capital Management Inc (Current Portfolio) buys Southern Co, Advanced Micro Devices Inc, Diageo PLC, Duke Energy Corp, Xcel Energy Inc, sells Tesla Inc, Biogen Inc, Yum China Holdings Inc, UiPath Inc, CymaBay Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, LCM Capital Management Inc.

Yahoo | January 24, 2022

Trade Alert: The Chief Medical Officer Of CymaBay Therapeutics, Inc. (NASDAQ:CBAY), Dennis Kim, Has Just Spent US$61k Buying A Few More Shares

Even if it's not a huge purchase, we think it was good to see that Dennis Kim, the Chief Medical Officer of CymaBay...

Yahoo | January 22, 2022

CymaBay Therapeutics Inc. (CBAY) Moves to Buy: Rationale Behind the Upgrade

CymaBay Therapeutics Inc. (CBAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | January 11, 2022

Read More 'CBAY' Stories Here

CBAY Price Returns

1-mo -13.62%
3-mo -37.15%
6-mo -41.33%
1-year -52.01%
3-year -83.08%
5-year -55.58%
YTD -39.94%
2021 -41.11%
2020 192.86%
2019 -75.10%
2018 -14.46%
2017 431.79%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5977 seconds.